245 related articles for article (PubMed ID: 31129768)
21. Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression.
Acosta-Gonzalez G; Ouseph M; Lombardo K; Lu S; Glickman J; Resnick MB
Hum Pathol; 2019 Jan; 83():115-123. PubMed ID: 30172913
[TBL] [Abstract][Full Text] [Related]
22. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
23. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
Chang AMV; Chiosea SI; Altman A; Pagdanganan HA; Ma C
Head Neck Pathol; 2017 Jun; 11(2):203-211. PubMed ID: 27807760
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
Watson MM; Lea D; Gudlaugsson E; Skaland I; Hagland HR; Søreide K
Cancer Immunol Immunother; 2020 Aug; 69(8):1627-1637. PubMed ID: 32314040
[TBL] [Abstract][Full Text] [Related]
25. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer.
Wu Y; Cao D; Qu L; Cao X; Jia Z; Zhao T; Wang Q; Jiang J
Oncotarget; 2017 Sep; 8(38):64066-64082. PubMed ID: 28969052
[TBL] [Abstract][Full Text] [Related]
26. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
27. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
28. Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer.
Enkhbat T; Nishi M; Takasu C; Yoshikawa K; Jun H; Tokunaga T; Kashihara H; Ishikawa D; Shimada M
Anticancer Res; 2018 Jun; 38(6):3367-3373. PubMed ID: 29848685
[TBL] [Abstract][Full Text] [Related]
29. Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy.
Dunne PD; McArt DG; O'Reilly PG; Coleman HG; Allen WL; Loughrey M; Van Schaeybroeck S; McDade S; Salto-Tellez M; Longley DB; Lawler M; Johnston PG
Cancer Immunol Res; 2016 Jul; 4(7):582-91. PubMed ID: 27197062
[TBL] [Abstract][Full Text] [Related]
30. PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.
Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H
Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459
[TBL] [Abstract][Full Text] [Related]
31. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
[TBL] [Abstract][Full Text] [Related]
32. [Expression level and prognostic value of PD-L1 in microsatellite instability-high gastric cancer].
Wang XY; Hu YJ; Dong K; Zhao C; Huang XZ; Lian SY; Sun Y
Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1114-1119. PubMed ID: 33152814
[No Abstract] [Full Text] [Related]
33. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
[TBL] [Abstract][Full Text] [Related]
34. Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma.
Nam SJ; Kim YH; Park JE; Ra YS; Khang SK; Cho YH; Kim JH; Sung CO
Cancer Immunol Immunother; 2019 Feb; 68(2):305-318. PubMed ID: 30483834
[TBL] [Abstract][Full Text] [Related]
35. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.
Di Bartolomeo M; Morano F; Raimondi A; Miceli R; Corallo S; Tamborini E; Perrone F; Antista M; Niger M; Pellegrinelli A; Randon G; Pagani F; Martinetti A; Fucà G; Pietrantonio F;
Oncologist; 2020 Mar; 25(3):e460-e468. PubMed ID: 32162808
[TBL] [Abstract][Full Text] [Related]
36. Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer.
Yuan W; Deng D; Jiang H; Tu C; Shang X; He H; Niu R; Dong J
Cancer Immunol Immunother; 2019 Feb; 68(2):257-268. PubMed ID: 30406373
[TBL] [Abstract][Full Text] [Related]
37. Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features.
Watari J; Mitani S; Ito C; Tozawa K; Tomita T; Oshima T; Fukui H; Kadowaki S; Natsume S; Senda Y; Tajika M; Hara K; Yatabe Y; Shimizu Y; Muro K; Morimoto T; Hirota S; Das KM; Miwa H
Sci Rep; 2019 Jul; 9(1):10526. PubMed ID: 31324814
[TBL] [Abstract][Full Text] [Related]
38. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
39. PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
Schneider S; Kadletz L; Wiebringhaus R; Kenner L; Selzer E; Füreder T; Rajky O; Berghoff AS; Preusser M; Heiduschka G
Histopathology; 2018 Oct; 73(4):573-584. PubMed ID: 29742291
[TBL] [Abstract][Full Text] [Related]
40. PD-1/PD-L1-dependent immune response in colorectal cancer.
Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]